MétaCan
Menu
Back to cohort

055 Can interleukin IL-17A levels predict response to biologic treatment in patients with rheumatoid arthritis?

2019· article· en· W2937526802 on OpenAlexaff
Stephen McDonald, Rachel Reed, Ivona Baričević-Jones, Stephanie F Ling, Darren Plant, Anne Barton

Bibliographic record

VenueLara D. Veeken · 2019
Typearticle
Languageen
FieldImmunology and Microbiology
TopicPsoriasis: Treatment and Pathogenesis
Canadian institutionsDiscovery Centre
Fundersnot available
KeywordsRheumatoid arthritisMedicineInterleukin 17ImmunologyInterleukinImmune systemCytokine

Abstract

fetched live from OpenAlex

Background: The cytokine interleukin IL-17A has an important pro-inflammatory role; it stimulates IL-1 and tumour necrosis factor (TNF) production, induces IL-6 secretion and upregulates RANK-ligand, which promotes bone erosion. We hypothesised that patients whose disease activity is not adequately controlled by TNF therapies in rheumatoid arthritis (RA) may have IL-17 driven disease. Our aim was to determine if pre-treatment or 3 month IL-17A concentrations correlate with treatment response to anti-TNF drugs by 6 months of treatment. Methods: Patient data was collected as part of the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS). Patients were followed up at pre-treatment (baseline), 3 months, 6 months and 12 months with blood samples, patient questionnaires and clinical data obtained. RA patients were eligible for inclusion if they were commencing on adalimumab or etanercept. Patients were designated good or poor EULAR responder status at 6-month follow-up. Wilcoxon rank sum was used to compare IL-17A levels at pre-treatment and 3 months- according to EULAR classification by 6 months. A logistic regression analysis was carried out with regards to gender, baseline DMARD use and disease activity scores (DAS-28). Results: 152 patients were included, with 80 patients treated with adalimumab and 72 with etanercept. There was no statistically significant difference between mean IL-17A levels at baseline and 3-month follow-up in the group as a whole (p = 0.77). Nor was there any statistically significant difference between mean IL-17A levels at baseline and 3 months in either the adalimumab (p = 0.21) or etanercept treatment groups (0.22). In good responders, the mean serum levels of IL-17A increased from 1.06 pg/ml at baseline to 1.23pg/ml at 3 months. This came close to statistical significance (p = 0.07). In poor responders, the mean IL-17A levels actually decreased from 1.29pg/ml to 1.18pg/ml (p = 0.49). Adjusting for gender, baseline DMARD use and DAS-28 scores did not alter our findings. Conclusion: An increase in IL17-A serum levels between baseline and 3 months may be associated with a good EULAR response status by 6 months but larger sample sizes are required to confirm this. Disclosures: S. McDonald: None. R. Reed: None. I. Baricevic-Jones: None. S. Ling: None. D. Plant: None. A. Barton: None.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.004
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.216
Teacher spread0.204 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueLara D. VeekenSame topicPsoriasis: Treatment and PathogenesisFrench-language works237,207